Curcumin Loaded Dendrimers Specifically Reduce Viability of Glioblastoma Cell Lines.
PAMAM dendrimers
cancer
curcumin
glioblastoma
nano-molecule
therapy
toxicology
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
06 Oct 2021
06 Oct 2021
Historique:
received:
20
08
2021
revised:
25
09
2021
accepted:
30
09
2021
entrez:
13
10
2021
pubmed:
14
10
2021
medline:
17
11
2021
Statut:
epublish
Résumé
Glioblastoma (GB) is a deadly and aggressive cancer of the CNS. Even with extensive resection and chemoradiotherapy, patient survival is still only 15 months. To maintain growth and proliferation, cancer cells require a high oxidative state. Curcumin, a well-known anti-inflammatory antioxidant, is a potential candidate for treatment of GB. To facilitate efficient delivery of therapeutic doses of curcumin into cells, we encapsulated the drug in surface-modified polyamidoamine (PAMAM) dendrimers. We studied the
Identifiants
pubmed: 34641594
pii: molecules26196050
doi: 10.3390/molecules26196050
pmc: PMC8512379
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Dendrimers
0
Drug Carriers
0
Poly(amidoamine)
0
Polyamines
0
Curcumin
IT942ZTH98
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NEI NIH HHS
ID : R21 EY030012
Pays : United States
Références
BMC Cancer. 2020 Aug 24;20(1):791
pubmed: 32838749
BMC Neurol. 2009 Jun 12;9 Suppl 1:S2
pubmed: 19534731
Curr Pharm Des. 2013;19(11):2101-13
pubmed: 23116316
Behav Brain Res. 2011 Mar 1;217(2):369-78
pubmed: 21070819
PLoS One. 2019 Dec 16;14(12):e0225660
pubmed: 31841506
J Phys Chem B. 2005 Jan 20;109(2):692-704
pubmed: 16866429
Int J Mol Sci. 2017 Mar 14;18(3):
pubmed: 28335421
J Biol Chem. 2010 Dec 17;285(51):39759-67
pubmed: 20870728
Cancer Res. 2017 Feb 15;77(4):823-826
pubmed: 28159862
J Mol Neurosci. 2020 Oct;70(10):1471-1483
pubmed: 32666415
ACS Omega. 2020 Jan 07;5(2):1120-1126
pubmed: 31984268
Eur J Pharm Biopharm. 2013 Nov;85(3 Pt A):452-62
pubmed: 23891772
Profiles Drug Subst Excip Relat Methodol. 2014;39:113-204
pubmed: 24794906
Chin J Cancer Res. 2011 Sep;23(3):218-23
pubmed: 23467256
Toxicol Appl Pharmacol. 2007 Nov 15;225(1):70-9
pubmed: 17764713
Clin Cancer Res. 2008 Jul 15;14(14):4491-9
pubmed: 18628464
Mol Pharm. 2007 Nov-Dec;4(6):807-18
pubmed: 17999464
Drug Resist Updat. 2015 Mar;19:1-12
pubmed: 25791797
Int J Nanomedicine. 2020 Apr 23;15:2789-2808
pubmed: 32368055
Ann Indian Acad Neurol. 2008 Jan;11(1):13-9
pubmed: 19966973
Genes Dis. 2016 May 11;3(3):198-210
pubmed: 30258889
Clin Cancer Res. 2001 Jul;7(7):1894-900
pubmed: 11448902
Cell Div. 2008 Oct 03;3:14
pubmed: 18834508
Clin Transl Oncol. 2016 Nov;18(11):1062-1071
pubmed: 26960561
Front Microbiol. 2017 Jun 20;8:1014
pubmed: 28676790
Stem Cell Res Ther. 2015 Feb 19;6:9
pubmed: 25971780
J Clin Neurosci. 2012 Nov;19(11):1530-4
pubmed: 22989795
J Biol Regul Homeost Agents. 2013 Jan-Mar;27(1):105-19
pubmed: 23489691
Regul Toxicol Pharmacol. 1993 Feb;17(1):85-94
pubmed: 8441831
J Biol Chem. 2004 Sep 17;279(38):39872-9
pubmed: 15254031